Compare Cassava Sciences Inc (FLNA) vs Innodata Inc (INOD) Price & Performance

FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.

The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.

INOD is trading at $61.20, down 3.49% today, showing bearish technical signals despite strong fundamental performance. The company has consistently beaten earnings expectations in recent quarters with Q1 2026 EPS of $0.42 versus $0.13 expected. Revenue growth accelerated from $252M in 2025 to $317M in 2026, while net profit margins improved from 12.78% to 14.65%. Recent developments include the opening of a motion-capture AI lab and board appointments strengthening cybersecurity expertise.

The stock presents a growth opportunity with strong AI data engineering positioning and expanding margins, but faces headwinds from premium valuation (P/E 47.43) and technical weakness. Key risks include customer concentration and competitive pressures in the AI services sector. Analyst consensus remains bullish with 4 buy ratings versus 2 holds, suggesting potential upside if execution continues.